Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products

Human Gene Therapy

Volumn 11, Issue 3, 2000, Pages 415-427

  Christ, Marielle ^a   Louis, Bernard ^b   Stoeckel, Fabienne ^a   Dieterle, Annick ^a   Grave, Linda ^a   Dreyer, Dominique ^a   Kintz, Jacqueline ^a   Ali Hadji, Dalila ^a   Lusky, Monika ^a   Mehtali, Majid ^a  

^a TRANSGENE S A   (France)

^b Cabinet de Pathologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; COMPLEMENTARY DNA; GENE PRODUCT; VIRUS DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; INFLAMMATION; LIVER TOXICITY; MOUSE; NONHUMAN; OPEN READING FRAME; TRANSGENE; VIRUS GENE;

ADENOVIRIDAE; ADENOVIRUS E4 PROTEINS; ANIMALS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENE DELETION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATITIS, TOXIC; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; OPEN READING FRAMES; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; DNA VIRUSES;

EID: 0034628484     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015888     Document Type: Article

References (58)

1. ARMENTANO, D., ZABNER, J., SACKS, C., SOOKDEO, C.C., SMITH., M.P., ST. GEORGE, J.A., WADSWORTH, S.C., SMITH, A.E., and GREGORY, R.J. (1997). Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71, 2408-2416.
2. ARMENTANO, D., SMITH, M.P., SOOKDEO, C.C., ZABNER, J., PERRICONE, M.A., ST. GEORGE, J.A., WADSWORTH, S.C., and GREGORY, R.J. (1999). E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors. J. Virol. 73, 7031-7034.
3. BARR, D., TUBB, J., FERGUSSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
4. BELLON, G., MICHEL-CALEMARD, L., THOUVENOT, D., JAGNEAUX, V., POITEVIN, F., MALCUS, C., ACCART, N., LAYANI, M.P., AYMARD, M., BERNON, H., BIENVENU, J., COURTNEY, M., DÖRING, G., GILLY, B., GILLY, R., LAMY, D., LEVREY, H., MOREL, Y., PAULIN, C., PERRAUD, F., RODILLON, L., SENÉ, C., SO, S., TOURAINE-MOULIN, F., SCHATZ, C., and PAVIRANI, A. (1997). Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial. Hum. Gene Ther. 8, 15-25.
5. BERKNER, K.L. (1988). Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6, 616-629.
6. BOWLES, N.E., and WANG, Q. (1997). Prospect for adenovirus-mediated gene therapy of inherited diseases of the myocardium. Cardiovasc. Res. 35, 422-430.
7. BRIDGE, E., and KETNER, G. (1989). Redundant control of adenovirus late gene expression by early region 4. J. Virol. 63, 631-638.
8. BRIDGE, E., MEDGHALCHI, S., UBOL, S., LEESONG, M., and KETNER, G. (1993). Adenovirus early region 4 and viral DNA synthesis. Virology 193, 794-801.
9. BROUGH, D.E., HSU, C., KULESA, V.A., LEE, G.M., CANTOLUPO, L.J., LIZONOVA, A., and KOVESDI, I. (1997). Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J. Virol. 71, 9206-9213.
10. CHALLBERG, S.S., and KETNER, G. (1981). Deletion mutants of adenovirus 2: Isolation and initial characterization of virus carrying mutations near the right end of the viral genome. Virology 114, 196-209.
11. CHARTIER, C, DEGRYSE, E., GANTZER, M., DIETERLE, A., PAVIRANI, A., and MEHTALI, M. (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70, 4805-4810.
12. CHRIST, M., LUSKY, M., STOECKEL, F., DREYER, D., DIETERLÉ, A., MICHOU, A.I., PAVARINI, A., and MEHTALI M. (1997). Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response. Immunol. Lett. 57, 19-25.
13. CHROBOCZEK, J., BIEBER, F., and JACROT, B. (1992). The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186, 280-285.
14. CLAYMAN, G.L., EL-NAGGAR, A.K., LIPPMAN, S.M., HENDERSON, Y.C., FREDERICK, M., MERRITT, J.A., ZUMSTEIN, L.A., TIMMONS, T.M., LIU, T.J., GINSBERG, L., ROTH, J.A., HONG, W.K., BRUSO, P., and GOEPFERT, H. (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232.
15. CLESHAM, G.J., ADAM, P.J., PROUDFOOT, D., FLYNN, P.D., EFSTATHIOU, S., and WEISSBERG, P.L. (1998). High adenoviral loads stimulate NfκB-dependent gene expression in human vascular smooth muscle cells. Gene Ther. 5, 174-180.
16. COLLINS, T. (1993). Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab. Invest. 68, 499-508.
17. CONNELLY, S., SMITH, T.A.G., DHIR, G., GARDNER, J.M., MEHAFFEY, M.G., ZARET, K.S., MCLELLAND, A., and KALEKO, M. (1995). In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther. 6, 185-193.
18. CRYSTAL, R.G., MCELVANEY, N.G., ROSENFELD, M.A., CHU, C.-S., MASTRANGELI, A., HAY, J.G., BRODY, S.L., JAFFE, H.A., EISSA, N.T., and DANIEL, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet. 8, 42-51.
19. DEDIEU, J.F., VIGNE, E., TORRENT, C., JULLIEN, C, MAHFOUZ, I., CAILLAUD, J.M., AUBAILLY, N., ORISINI, C., GUILLAUME, J.M., OPOLON, P., DELAERE, P., PERRICAUDET, M., and YEH, P. (1997). Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71, 4626-4637.
20. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994a). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
21. ENGELHARDT, J.F., LITZKY, L., and WILSON, J.M. (1994b). Prolonged transgene expression in cotton rat lung with recombinant adenoviruses in E2a. Hum. Gene Ther. 5, 1217-1229.
22. FALLAUX, F., BOUT, A., VAN DER VELDE, I., VAN DEN WOLLENBERG, D.J., HEHIR, K.M., KEEGAN, J., AUGER, C., CRAMER, S.J., VAN ORMONDT, H., VAN DER EB, A.J., VALERIO, D., and HOEBEN, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
23. - recombinant adenoviral vectors containing a temperature sensitive E2a mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 3, 217-222.
24. GAHÉRY-SÉGARD, H., JUILLARD, V., GASTON, J., LENGAGNE, R., PAVIRANI, A., BOULANGER, P., and GUILLET, J.G. (1997a). Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced Ig subclass shifts. Eur. J. Immunol. 27, 653-659.
25. GAHÉRY-SÉGARD, H., MOLINIER-FRENKEL, V., LE BOULAIRE, C., SAULNIER, P., APOLON, P., LENGAGNE, R., GAUTIER, E., LE CESNE, A., ZITVOGEL, L., VENET, A., SCHATZ, C., COURTNEY, M., LECHEV ALIER, T., TURSZ, T., GUILLET, J.G., and FARACE, F. (1997b). Phase trial of recombinant adenovirus gene transfer in lung cancer: Longitudinal study of the immune response to transgene and viral products. J. Clin. Invest. 100, 2218-2226.
26. GAO, G.P., YANG, Y., and WILSON, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.
27. GORZIGLIA, M.I., KADAN, M.J., YEI, S., LIM, J., LEE, G.M., LUTHRA, R., and TRAPNELL, B.C. (1996). Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70, 4173-4178.
28. GRAHAM, F.L., and PREVEC, L. (1992). Adenovirus based expression vectors and recombinant vaccines. In: Vaccines: New Approaches to Immunological Problems. R.W. Ellis, ed. (Butterworth-Heinemann, Newton, MA) pp. 363-390.
29. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72.
30. HUANG, M.-M., and HEARING, P. (1989). The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor E2F, through a direct complex. Genes Dev. 3, 1699-1710.
31. IMLER, J.L., BOUT, A., DREYER, D., DIETERLÉ, A., SCHULTZ, H., VALÉRIO, D., MEHTALI M., and PAVIRANI, A. (1995). Trans-complementation of E1-deleted adenovirus: A new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses. Hum. Gene Ther. 6, 711-721.
32. JUILLARD, V., VILLEFROY, P., GODFRIN, D., PAVIRANI, A., VENET, A., and GUILLET, J.G. (1995). Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Virol. 25, 3467-3473.
33. KAFRI, T., MORGAN, D., KRAHL, T., SARVETNICK, N., SHERMAN, L., and VERMA, I. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 95, 11377-11382.
34. KASS-EISSLER, A., FALCK-PEDERSEN, E., ELFENBEIN, D.H., ALVIRA, M., BUTTRICK, P.M., and LEINWAND, L.A. (1994). The impact of development stage, route of administration, and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1, 395-402.
35. LAVOIE, J.N., NGUYEN, M., MARCELLUS, R.C., BRANTON, P.E., and SHORE, G.C. (1998). E4orf4, a novel adenovirus death adenovirus that induces p53-independent apoptosis by a pathway which is not inhibited by zVAD-fmk. J. Cell Biol. 140, 637-645.
36. LEPPARD, K.N. (1997). E4 gene function in adenovirus, adenovirus-vector and adeno-associated virus infections. J. Gen.Virol. 78, 2131-2138.
37. LI, Q., KAY, M.A., FINEGOLD, M., STRATFORD-PERRICAUDET, L.D., and WOO, S.L. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4, 403-409.
38. LUSKY, M., CHRIST, M., RITTNER, K., DIETERLÉ, A., DREYER, D., MOUROT, B., SCHULTZ, H., STOECKEL, F., PAVIRANI, A., and MEHTALI, M. (1998). in vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72, 2022-2032.
39. LUSKY, M., GRAVE L., DIETERLE, A., DREYER, D., CHRIST, M., ZILLER, C.H., FURSTENBERGER, P., KINTZ, J., ALI-HADJI, D., PAVIRANI, A., and MEHTALI M. (1999). Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: Requirement of E4ORF3. J. Virol. 73, 8308-8319.
40. MARCELLUS, R.C., LAVOIE, J.N., BOIVIN, D., SHORE, G.C., KETNER, G., and BRANTON, P.E. (1998). The early region 4 orf4 protein of human adenovirus type 5 induces p53-independant cell death by apoptosis. J. Virol. 72, 7144-7153.
41. MICHOU, A.I., SANTORO, L., CHRIST, M., JULLIARD, V., PAVIRANI, A., and MEHTALI, M. (1997). Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4, 473-482.
42. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovectors for gene therapy. J. Virol. 70, 7498-7509.
43. MORRAL, N., O'NEAL, W., ZHOU, H., LANGSTON, C., and BEAUDET, A. (1997). Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther. 8, 1275-1286.
44. O'NEAL, W.K, ZHOU, H., MORRAL, N., AGUILAR-CORDOVA, E., PESTANER, J., LANGSTON, C., MULL, B., WANG, Y., BEAUDET, A.L., and LEE, B. (1998). Toxicological comparison of E2a-deleted and first generation adenoviral vectors expressing α1-antitrypsin after systemic delivery. Hum. Gene Ther. 9, 1587-1598.
45. OTAKE, K., ENNIST, D.L., HARROD, K., and TRAPNELL, B.C. (1998). Non-specific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum. Gene Ther. 10, 2207-2222.
46. RITTNER, K., SCHULTZ, H., PAVIRANI, A., and MEHTALI, M. (1997). Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. J. Virol. 71, 3307-3311.
47. SHENK, T. (1996). Adenoviridae: the viruses and their replication. In Virology. D.M. Knipe, P.M. Howley, et al, eds. (Raven Press, Philadelphia) pp. 2111-2148.
48. SHTRICHMAN, R., and KLEINBERGER, T. (1998). Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells. J. Virol. 72, 2975-2982.
49. SONG, W., KONG, H.-L., TRAKTMAN, P., and CRYSTAL, R.G. (1997). Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum. Gene Ther. 8, 1207-1217.
50. TRAPNELL, B.C. (1993). Adenoviral vectors for gene transfer. Adv. Drug Deliv. Rev. 12, 185-199.
51. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
52. WANG, Q., GREENBURG, G., BUNCH, D., FARSON, D., and FINER, M.H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther. 4, 393-400.
53. YANG, Y., NUNES, F.A., BERENCSI, K., GÖNCZÖL, E., ENGELHARDT, J.F., and WILSON, J.M.. (1994). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7, 362-369.
54. YANG, Y., LIN, Q., ERTL, H.C.J., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
55. YANG, Y., JOOSS, K.U., SU, Q., ERTL, H.C.J., and WILSON, J.M. (1996a). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
56. YANG, Y., SU, Q., and WILSON, J.M. (1996b). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70, 7209-7212.
57. YAO, S.N., FARJO, A., ROESSLER, B.J., DAVIDSON, B.L., and KURACHI, K. (1996). Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: Evidence for prolonged stability and activity of the transgene in liver. Viral Immunol. 9, 141-153.
58. YEH, P., DEDIEU, J.F., ORSINI, C., VIGNE, E., DENEFLE, P., and PERRICAUDET, P. (1996). Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70, 559-565.